{"groups":[{"description":"Participants received vandetanib 300 mg orally once daily until objective disease progression, any other withdrawal criteria was met or at the investigator's discretion, the approval and implementation of protocol amendment 6 during the blinded randomized treatment period. Upon disease progression or implementation of protocol amendment 6, participants who were unblinded were given the option to enter the open-label treatment period and continue to receive vandetanib 300 mg orally once daily for as long as they still benefitted of it per investigator judgement or until they were given another anti-cancer therapy.","id":"FG000","title":"Vandetanib 300 mg/Vandetanib 300 mg"},{"description":"Participants received placebo matched to vandetanib orally once daily until objective disease progression, any other withdrawal criteria was met or at the investigator's discretion, the approval and implementation of protocol amendment 6 during the blinded randomized treatment period. Upon disease progression or implementation of protocol amendment 6, participants who were unblinded were given the option to enter the open-label treatment period and receive vandetanib 300 mg orally once daily for as long as they still benefitted of it per investigator judgement or until they were given another anti-cancer therapy.","id":"FG001","title":"Placebo/Vandetanib 300 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"3"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"103"},{"groupId":"FG001","numSubjects":"68"}],"type":"Objective Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"6"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"69"},{"groupId":"FG001","numSubjects":"21"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Randomized but did not Receive Treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"231"},{"groupId":"FG001","numSubjects":"100"}],"comment":"Randomized participants.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"231"},{"groupId":"FG001","numSubjects":"99"}],"type":"Received Randomized Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"1"}],"comment":"Participants who ended randomized treatment.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"217"},{"groupId":"FG001","numSubjects":"99"}],"type":"NOT COMPLETED"}],"title":"Randomized Treatment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"15"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"27"}],"type":"Objective Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"7"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"9"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"109"},{"groupId":"FG001","numSubjects":"79"}],"comment":"Participants who discontinued randomized treatment and received open-label treatment (vandetanib 300 mg).","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"21"}],"comment":"Participants who ended open-label treatment (vandetanib 300 mg).","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"81"},{"groupId":"FG001","numSubjects":"58"}],"type":"NOT COMPLETED"}],"title":"Open-Label Treatment Period"}],"recruitmentDetails":"A total of 331 participants were enrolled in the study. The study was conducted at 60 study sites in 23 countries. First participant enrolled 23 November 2006, last participant enrolled 19 October 2007."}